How Long After Ketamine Can You Safely Drive?

Most clinical guidelines recommend waiting at least 12 to 24 hours after receiving ketamine before getting behind the wheel, though the exact window depends on the dose, the route of administration, and whether other sedating substances are involved. That range surprises some people who feel clear-headed within a couple of hours, but the drug’s effects on reaction time, visual tracking, and divided attention can linger well past the point where you stop feeling “high.” The gap between subjective recovery and measurable impairment is the core safety issue, and it is wider than most patients expect.

What Ketamine Does to the Skills You Need for Driving

Driving draws on several brain functions at once: you track moving objects in your peripheral vision, react quickly to sudden changes, hold a route plan in working memory, and adjust your steering in small, continuous corrections. Ketamine disrupts virtually all of these. In healthy volunteers, even analgesic (sub-anesthetic) doses produced measurable drops in psychomotor speed, reaction time, and cognitive flexibility, along with memory impairment and a subjective feeling of intoxication.¹ Those are exactly the capacities that keep you in your lane and responsive to brake lights ahead.

Ketamine also affects the eyes. Research on eye-movement patterns shows that the drug reduces the speed and range of saccades, the rapid eye movements you use to scan the road and mirrors. Fixation durations get longer, meaning the eyes linger on one spot rather than sweeping the visual field efficiently.² Separately, ketamine increases the number of leading saccades during smooth-pursuit tracking, the kind of eye movement you rely on when following a car ahead of you through a curve.³ Together, these effects amount to a narrower, jerkier visual scan of the road, which is dangerous even at moderate speeds.

How Long Ketamine Stays Active in Your Body

Ketamine is cleared relatively quickly compared with many sedatives. After a single intravenous dose, the elimination half-life is roughly two to four hours.⁴ In critically ill patients the half-life can stretch to about five hours, and repeated or prolonged dosing extends clearance even further, with one review noting elimination times as long as 11 days after frequent repeated doses.⁴

The parent drug is only part of the story. Your liver converts ketamine into norketamine, an active metabolite that still has sedating and dissociative properties, though weaker than the parent molecule. Norketamine hangs around longer; in one study involving children who received a single IV dose, norketamine was detected in urine up to 14 days later.⁴ Another metabolite, 5,6-dehydronorketamine, has an even longer plasma presence and has been detected six to ten days after dosing.⁴ Detection in a urine or blood test is not the same as impairment, but these long tails explain why residual cognitive effects can persist well beyond the point where you feel sober.

Individual variation matters too. The primary enzyme responsible for breaking down ketamine is CYP3A4, with CYP2B6 and CYP2C9 playing smaller roles at therapeutic concentrations.⁴ If you take medications that inhibit CYP3A4, such as certain antifungals, macrolide antibiotics, or grapefruit juice in large quantities, ketamine will clear more slowly. People with liver impairment face the same problem. That two-to-four-hour half-life is a population average, not a personal guarantee.

What Driving Studies Actually Show

Simulator research gives us the most direct picture of ketamine’s impact on driving. A study using escalating sub-anesthetic doses of IV ketamine tracked participants’ lane-keeping and steering variability in a validated driving simulator. At every active dose level, participants swerved more than at baseline. At the highest dose, the lane-weaving reached levels that researchers described as incompatible with safe driving. The encouraging finding was that when participants were tested two hours after the infusion ended, their simulated driving performance returned to baseline.⁵

That two-hour recovery sounds reassuring, but there are important caveats. These were healthy volunteers receiving carefully controlled doses in a clinical setting, not people receiving repeated infusions or taking recreational doses of unknown purity. And a driving simulator, even a validated one, does not replicate the full cognitive load of real traffic, where you deal with unexpected pedestrians, construction detours, and highway merges all at once.

The picture gets more complicated when ketamine is combined with other drugs, as it often is in clinical practice. When ketamine was given alongside dexmedetomidine, a sedative sometimes used as an adjunct, participants still showed significantly impaired lane-keeping and reduced steering variability two hours after treatment. The combination with fentanyl, by contrast, did not produce the same degree of impairment at the two-hour mark.⁶ The lesson is that the adjunct drug matters enormously. If your ketamine session includes another sedating medication, the two-hour “back to baseline” finding does not apply to you.

The Esketamine Nasal Spray Difference

Esketamine, the S-enantiomer of ketamine, is delivered as a nasal spray under the brand name Spravato for treatment-resistant depression. Its dosing regimen and pharmacokinetics differ from IV ketamine, and there is specific driving data for it. A real-world on-road driving study in patients with major depressive disorder found that a single dose of esketamine did not impair driving performance the next morning. When the study looked at repeated dosing over three weeks, same-day driving performance after each session also showed no meaningful difference from placebo.⁷

This does not mean you can drive the same afternoon after a Spravato session. The FDA-approved label still requires patients to be monitored in-clinic for at least two hours post-dose and instructs them not to drive for the rest of the day. The study’s results are encouraging for next-day safety, but clinics follow the conservative label guidance for good reason: individual responses vary, and the study’s participants were under controlled conditions with stable dosing.

Why Feeling Fine Is a Poor Indicator

One of the trickiest aspects of ketamine recovery is that subjective recovery runs ahead of objective recovery. Patients who say they feel alert and ready to drive may still show measurable deficits on divided-attention tasks. In one study comparing ketamine to another drug, those who received ketamine reported more sleepiness and rated their own driving ability and confidence as lower.⁸ That self-awareness actually makes ketamine somewhat unusual among impairing substances; people often accurately perceive that something is off. The problem is that a meaningful minority decide to drive anyway.

A broader review of driving ability after conscious sedation with various agents found that impairment in real and simulated driving, as well as in psychomotor and cognitive tasks like reaction time and body sway, can persist anywhere from half an hour to ten hours after drug administration, depending on the agent and dose. Ketamine falls within that range, but tends toward the longer end when higher doses or repeated infusions are involved.

The conservative approach used by most ketamine clinics, requiring someone else to drive you home and asking that you not drive until at least the next day, reflects this disconnect between how you feel and how you perform. For anesthesia or deep sedation of any kind, published clinical recommendations suggest waiting 24 to 48 hours before driving, scaled by how long the sedation lasted.

Alcohol and Other Substances That Widen the Window

Ketamine and alcohol share several pharmacological targets in the brain, and using both even hours apart can amplify impairment beyond what either would produce alone. Researchers have hypothesized that the combination synergistically intensifies toxicological consequences, including the cognitive and motor effects most relevant to driving.⁹ If you had a ketamine treatment in the afternoon and a glass of wine with dinner, you should not assume the two effects simply expire on independent timelines. They interact.

Benzodiazepines, opioids, antihistamines, and other CNS depressants raise similar concerns. Any medication that makes you drowsy on its own will compound ketamine’s residual sedation. If your provider prescribed a benzodiazepine for anxiety before a ketamine session, or if you take a sedating antihistamine at bedtime, the safe-to-drive window extends. The simulator study showing that ketamine paired with dexmedetomidine still impaired driving at two hours is a concrete illustration of how co-administered sedatives change the equation.

What Law Enforcement Tests For

Ketamine is classified alongside PCP in the Drug Evaluation and Classification Program used by trained drug-recognition officers in many countries. A study evaluating roadside impairment testing on 21 ketamine-only users found that typical signs included horizontal gaze nystagmus (involuntary eye jerking when looking to the side), elevated pulse rate, and failure of divided-attention tasks, especially walk-and-turn and one-leg-stand tests.¹⁰ These are the same standardized field sobriety tests used for alcohol, and ketamine users failed them at high rates.

The legal landscape is worth understanding. In many jurisdictions, driving under the influence of any impairing substance, not just alcohol, is a criminal offense. You do not need to be above a specific blood-ketamine threshold to be charged; demonstrable impairment is enough. And the numbers suggest the problem is real: a comprehensive review noted that in one Shanghai study, ketamine was the third most common illicit substance detected in drivers, that about a third of surveyed partygoers in a Scottish study admitted to driving after using ketamine, and that roughly one in ten drivers involved in fatal accidents in Hong Kong tested positive for the drug.¹¹ These statistics come from recreational-use contexts rather than clinical settings, but they underline how frequently people underestimate the drug’s duration of impairment.

Practical Timeline by Scenario

No single number works for everyone, but here is how the evidence shakes out for common situations:

Single low-dose IV infusion in a clinic: Simulator data suggests driving performance can return to baseline about two hours after the infusion ends, but most clinics and clinical guidelines recommend waiting until the following day. The conservative advice accounts for individual variation and for the fact that simulator recovery does not capture all real-world demands.
Higher-dose or repeated infusions: The safe window extends. Ketamine’s elimination slows with repeated dosing, and metabolite accumulation means residual sedation can persist. Waiting a full 24 hours is the minimum prudent choice; some providers recommend 48 hours.
Esketamine nasal spray (Spravato): Do not drive for the remainder of the day after your session. Next-morning driving appears safe based on on-road studies, consistent with the approved label guidance.
Ketamine combined with another sedative: Add time. The two-hour simulator benchmark does not apply when a second depressant is on board. Waiting until the next day is a reasonable minimum.
Recreational use of unknown dose: You have no way to verify the dose or purity, and the pharmacokinetic assumptions from clinical studies do not apply. Waiting at least 24 hours is the safest approach, longer if you feel any residual dissociation, unsteadiness, or visual disturbance.

The Role of Sleep

One often-overlooked factor is sleep quality the night after a ketamine session. Ketamine can disrupt normal sleep architecture, and a poor night of sleep compounds any lingering cognitive effects. If you received a late-afternoon infusion and then slept poorly, your reaction time the next morning may be worse than expected from the drug alone. The clinics that schedule sessions earlier in the day are partly doing this for recovery reasons: an earlier infusion gives both the drug and your sleep cycle more time to normalize before you need to drive.

If you wake up the morning after a session feeling groggy, mentally foggy, or not fully yourself, that is your body telling you recovery is still incomplete. Trusting that signal is more reliable than counting hours on a clock. The research consistently shows that divided-attention tasks and reaction-time measures are the last to normalize, and those are precisely the capacities that keep you safe in traffic.

When Metabolite Detection Differs from Impairment

Some patients worry about drug testing, whether for employment, legal, or insurance reasons, and conflate detection windows with impairment windows. The two are very different. The metabolite 5,6-dehydronorketamine can be detected in plasma for six to ten days after a single dose, and norketamine can appear in urine for up to two weeks.⁴ That does not mean you are impaired for two weeks. These trace metabolites exist at concentrations far below what would affect your cognition or motor skills. They matter for forensic analysis and workplace drug screens, not for driving fitness.

If you are a patient receiving therapeutic ketamine and face regular drug testing, the practical step is to keep documentation from your prescriber. A positive urine screen for ketamine metabolites long after your session is a lab result, not evidence of impairment. But if you are pulled over and an officer finds ketamine metabolites in oral fluid, the context of a clinical prescription may not prevent an arrest in the moment, even if it ultimately matters in court. Carrying proof of your prescription is a simple precaution that can save considerable hassle.